Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death

Published on Sep 13, 2016in JAMA45.54
· DOI :10.1001/JAMA.2016.12347
Ander Regueiro21
Estimated H-index: 21
(Laval University),
Axel Linke85
Estimated H-index: 85
(Leipzig University)
+ 62 AuthorsJosep Rodés-Cabau95
Estimated H-index: 95
(Laval University)
Importance Limited data exist on clinical characteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter aortic valve replacement (TAVR). Objective To determine the associated factors, clinical characteristics, and outcomes of patients who had infective endocarditis after TAVR. Design, Setting, and Participants The Infectious Endocarditis after TAVR International Registry included patients with definite infective endocarditis after TAVR from 47 centers from Europe, North America, and South America between June 2005 and October 2015. Exposure Transcatheter aortic valve replacement for incidence of infective endocarditis and infective endocarditis for in-hospital mortality. Main Outcomes and Measures Infective endocarditis and in-hospital mortality after infective endocarditis. Results A total of 250 cases of infective endocarditis occurred in 20 006 patients after TAVR (incidence, 1.1% per person-year; 95% CI, 1.1%-1.4%; median age, 80 years; 64% men). Median time from TAVR to infective endocarditis was 5.3 months (interquartile range [IQR], 1.5-13.4 months). The characteristics associated with higher risk of progressing to infective endocarditis after TAVR was younger age (78.9 years vs 81.8 years; hazard ratio [HR], 0.97 per year; 95% CI, 0.94-0.99), male sex (62.0% vs 49.7%; HR, 1.69; 95% CI, 1.13-2.52), diabetes mellitus (41.7% vs 30.0%; HR, 1.52; 95% CI, 1.02-2.29), and moderate to severe aortic regurgitation (22.4% vs 14.7%; HR, 2.05; 95% CI, 1.28-3.28). Health care–associated infective endocarditis was present in 52.8% (95% CI, 46.6%-59.0%) of patients. Enterococci species and Staphylococcus aureus were the most frequently isolated microorganisms (24.6%; 95% CI, 19.1%-30.1% and 23.3%; 95% CI, 17.9%-28.7%, respectively). The in-hospital mortality rate was 36% (95% CI, 30.0%-41.9%; 90 deaths; 160 survivors), and surgery was performed in 14.8% (95% CI, 10.4%-19.2%) of patients during the infective endocarditis episode. In-hospital mortality was associated with a higher logistic EuroSCORE (23.1% vs 18.6%; odds ratio [OR], 1.03 per 1% increase; 95% CI, 1.00-1.05), heart failure (59.3% vs 23.7%; OR, 3.36; 95% CI, 1.74-6.45), and acute kidney injury (67.4% vs 31.6%; OR, 2.70; 95% CI, 1.42-5.11). The 2-year mortality rate was 66.7% (95% CI, 59.0%-74.2%; 132 deaths; 115 survivors). Conclusions and Relevance Among patients undergoing TAVR, younger age, male sex, history of diabetes mellitus, and moderate to severe residual aortic regurgitation were significantly associated with an increased risk of infective endocarditis. Patients who developed endocarditis had high rates of in-hospital mortality and 2-year mortality.
Figures & Tables
📖 Papers frequently viewed together
2,090 Citations
2,518 Citations
40 Citations
Studies of infective endocarditis (IE) in transcatheter aortic valve replacement patients are limited by univariate analysis of predictors [(1)][1], incomplete patient data (particularly non-IE cases [[2]][2]), or low number of endpoints [(3)][3]. We aimed to investigate the incidence, treatment,
44 CitationsSource
#1Sebastiano Leone (UNISA: University of Salerno)H-Index: 24
#2S. Noviello (UNISA: University of Salerno)H-Index: 9
Last. Silvano Esposito (UNISA: University of Salerno)H-Index: 30
view all 3 authors...
Introduction Enterococci are common causes of infective endocarditis (IE) in both health care and community-based setting. Enterococcal IE requires bactericidal therapy for an optimal outcome. For decades, cell-wall-active antimicrobial agents (penicillins or vancomycin) in combination with aminoglycosides were the cornerstone of the treatment; however, the emergence of antibiotic resistance has significantly reduced the efficacy of these regimens.
12 CitationsSource
#1Gilbert HabibH-Index: 90
#2Patrizio LancellottiH-Index: 109
Last. David M. WalkerH-Index: 1
view all 20 authors...
158 CitationsSource
#1Manuel Martínez-Sellés (Hospital General Universitario Gregorio Marañón)H-Index: 18
#2Emilio BouzaH-Index: 101
Last. Patricia MuñozH-Index: 93
view all 12 authors...
AIMS: To describe the characteristics of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: This study was performed using the GAMES database, a national prospective registry of consecutive patients with IE in 26 Spanish hospitals. Of the 739 cases of IE diagnosed during the study, 1.3% were post-TAVI IE, and these 10 cases, contributed by five centres, represented 1.1% of the 952 TAVIs performed. Mean age was 80 years. All valves were implante...
27 CitationsSource
#1Gilbert HabibH-Index: 90
#2Patrizio LancellottiH-Index: 109
Last. José Luis ZamoranoH-Index: 82
view all 10 authors...
3D : three-dimensional AIDS : acquired immune deficiency syndrome b.i.d. : bis in die (twice daily) BCNIE : blood culture-negative infective endocarditis CDRIE : cardiac device-related infective endocarditis CHD : congenital heart disease CIED : cardiac implantable electronic device
2,090 CitationsSource
#2Marie-Claude MoriceH-Index: 64
Last. Peter Ludman (University of Birmingham)H-Index: 41
view all 14 authors...
Abstract Background There has been conflicting clinical evidence as to the influence of female sex on outcomes after transcatheter aortic valve replacement. Objectives The aim of this study was to evaluate the impact of sex on early and late mortality and safety end points after transcatheter aortic valve replacement using a collaborative meta-analysis of patient-level data. Methods From the MEDLINE, Embase, and the Cochrane Library databases, data were obtained from 5 studies, and a database co...
112 CitationsSource
#1Michael J. Reardon (Houston Methodist Hospital)H-Index: 57
#2David H. Adams (Mount Sinai Health System)H-Index: 14
Last. Jeffrey J. Popma (Harvard University)H-Index: 140
view all 27 authors...
Abstract Background The U.S. pivotal trial for the self-expanding valve found that among patients with severe aortic stenosis at increased risk for surgery, the 1-year survival rate was 4.9 percentage points higher in patients treated with a self-expanding transcatheter aortic valve bioprosthesis than in those treated with a surgical bioprosthesis. Objectives Longer-term clinical outcomes were examined to confirm if this mortality benefit is sustained. Methods Patients with severe aortic stenosi...
297 CitationsSource
#1Juan M. Pericàs (University of Barcelona)H-Index: 22
#2Jaume Llopis (University of Barcelona)H-Index: 14
Last. José M. Miró (University of Barcelona)H-Index: 77
view all 16 authors...
Summary Aims This study reports one case and review the literature on TAVI-associated endocarditis (TAVIE), to describe its clinical picture and to perform an analysis on prognostic factors. Methods and results A MEDLINE search from January 2002 to October 2014 revealed 31 cases of TAVIE, including 1 from our hospital. Median age was 81 years (IQR, 78–85), 53% of patients were males and the median age-adjusted Charlson score was 7 (IQR, 5–8). Heart failure was recorded in 42%, embolic events in ...
19 CitationsSource
Last. Josep Rodés-CabauH-Index: 95
view all 42 authors...
Background—We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). Methods and Results—This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who suffered IE after TAVI of 7944 patients after a mean follow-up of 1.1±1.2 years (incidence, 0.67%, 0.50% within the first year after TAVI). Mean time from TAVI was 6 months (interquartile range, 1–14 ...
141 CitationsSource
Background— Transcatheter aortic valve implantation (TAVI) is an advancing mode of treatment for inoperable or high-risk patients with aortic stenosis. Prosthetic valve endocarditis (PVE) after TAVI is a serious complication, but only limited data exist on its incidence, outcome, and procedural risk factors. Methods and Results— Observational single-center study of 509 consecutive patients treated with a transcatheter implanted self-expandable aortic valve prosthesis (Medtronic CoreValve). We id...
66 CitationsSource
Cited By144
#1Rachael R. Kirkbride (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 2
Last. Diana Litmanovich (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 24
view all 7 authors...
Infections of the cardiovascular system may present with nonspecific symptoms, and it is common for patients to undergo multiple investigations to arrive at the diagnosis. Echocardiography is central to the diagnosis of endocarditis and pericarditis. However, cardiac computed tomography (CT) and magnetic resonance imaging also play an additive role in these diagnoses; in fact, magnetic resonance imaging is central to the diagnosis of myocarditis. Functional imaging (fluorine-18 fluorodeoxyglucos...
2 CitationsSource
#1Saberio Lo PrestiH-Index: 5
#2Tarec K. ElajamiH-Index: 7
Last. Bo XuH-Index: 10
view all 0 authors...
#1Domenico Calcaterra (FAU: Florida Atlantic University)
#2Kevin M. HarrisH-Index: 32
Last. Ivan ChavezH-Index: 11
view all 0 authors...
Prosthetic valve endocarditis after transcatheter aortic valve implantation (TAVI) is a rare complication associated with a high mortality rate. Nonetheless, the rapid expansion of TAVI in recent years has proportionally increased the number of patients exposed to the risk of developing transcatheter valve infection. A 71-year-old female with recent history of TAVI was diagnosed with prosthetic valve obstruction secondary to endocarditis. The characteristics of clinical presentation of endocardi...
#1Dritan Useini (RUB: Ruhr University Bochum)H-Index: 5
#2Blerta BeluliH-Index: 1
Last. Justus Strauch (RUB: Ruhr University Bochum)H-Index: 19
view all 9 authors...
BACKGROUND A certain degree of prosthesis oversizing is recommended for the SAPIEN 3 (S3; Edwards Lifesciences Corp., Irvine, California, United States) to ensure device success. We aimed to investigate midterm outcomes in patients who received oversized (OS) S3 valve after transapical-transcatheter aortic valve replacement (TA-TAVR). METHODS Out of 122 patients with aortic stenosis who underwent TA-TAVR using S3 at our institution, 42 received OS prosthesis. We used computed tomography (CT) der...
ABSTRACT Despite significant diagnostic and therapeutic improvements, infective endocarditis (IE) still carries high morbidity and mortality. In the last three decades, significant variations in epidemiological and clinical profile of IE have been observed. The diagnosis of IE requires an adequate clinical suspicion, given its pleomorphic presentation. Microbiological and imaging techniques, which are pivotal in confirming the diagnosis, need constant refinement because of suboptimal accuracy. A...
1 CitationsSource
#1Jennifer Cruz (Hackensack University Medical Center)
#2Steven M. Hollenberg (Hackensack University Medical Center)H-Index: 24
#1Narut Prasitlumkum (UH: University of Hawaii)H-Index: 7
#2Sittinun Thangjui (Chula: Chulalongkorn University)H-Index: 2
Last. Ramdas G. Pai (UCR: University of California, Riverside)H-Index: 3
view all 6 authors...
: This study aimed to compare incidence of IE between BE and SE valves by performing a systematic review and meta-analysis of the literature. We comprehensively searched the databases of MEDLINE and EMBASE from inception to November 2019. Included studies were published observational studies that compared the risk of IE among patients undergoing TAVR employing BE versus SE valves, using the random-effects to calculate risk ratios and 95% confidence intervals (CIs).Ten cohort studies from April 2...
BACKGROUND The comparative mid and long-term durability, including the rates of bioprosthetic valve failure (BVF) of the Sapien XT® and Sapien 3® transcatheter heart valve (THV) in patients with intermediate surgical risk has not been reported. METHODS Consecutive intermediate-risk patients with severe aortic stenosis from the Mexican registry of transcatheter aortic valve replacement (TAVR) with Sapien® THVs were included. The primary endpoint was to compare the BVF rate between THVs at 2 years...
#1Michele GalloH-Index: 14
#2Michel Pompeu Barros de Oliveira Sá (UPE: Universidade de Pernambuco)H-Index: 20
Last. Enrico FerrariH-Index: 22
view all 8 authors...
INTRODUCTION Aortic and mitral bioprosthesis are the gold standard treatment to replace a pathological native valve. However, bioprostheses are prone to structural valve degeneration, resulting in limited long-term durability. During the past decade, the implantation of transcatheter stent-valves within degenerated aortic and mitral bioprostheses, (the so-called "valve-in-valve" procedure), represent a valid alternative to redo surgery in patients with high-risk surgical profiles. AREAS COVERED ...
#1E. PelceH-Index: 1
#2Alizée PortoH-Index: 3
Last. Alexis TheronH-Index: 12
view all 7 authors...
BACKGROUND This report presents 5-year outcomes of the rapid-deployment Edwards Intuity valve in a prospective, single-center study. METHODS All patients who underwent an aortic valve replacement (AVR) with an Edwards Intuity bioprosthesis at La Timone Hospital, Marseille, France, from July 2012 to June 2015 were assessed over a 5-year follow-up period. The primary outcome was overall mortality at 5 years. Secondary outcomes were reoperation, overall mortality and stroke, cardiovascular mortalit...
1 CitationsSource